Role of Respiratory Syncytial Virus in Pediatric Pneumonia

Sonia Bianchini, Ettore Silvestri, Alberto Argentiero, Valentina Fainardi, Giovanna Pisi, Susanna Esposito, Sonia Bianchini, Ettore Silvestri, Alberto Argentiero, Valentina Fainardi, Giovanna Pisi, Susanna Esposito

Abstract

Respiratory viral infections represent the leading cause of hospitalization in infants and young children worldwide and the second leading cause of infant mortality. Among these, Respiratory Syncytial Virus (RSV) represents the main cause of lower respiratory tract infections (LRTIs) in young children worldwide. RSV manifestation can range widely from mild upper respiratory infections to severe respiratory infections, mainly bronchiolitis and pneumonia, leading to hospitalization, serious complications (such as respiratory failure), and relevant sequalae in childhood and adulthood (wheezing, asthma, and hyperreactive airways). There are no specific clinical signs or symptoms that can distinguish RSV infection from other respiratory pathogens. New multiplex platforms offer the possibility to simultaneously identify different pathogens, including RSV, with an accuracy similar to that of single polymerase chain reaction (PCR) in the majority of cases. At present, the treatment of RSV infection relies on supportive therapy, mainly consisting of oxygen and hydration. Palivizumab is the only prophylactic method available for RSV infection. Advances in technology and scientific knowledge have led to the creation of different kinds of vaccines and drugs to treat RSV infection. Despite the good level of these studies, there are currently few registered strategies to prevent or treat RSV due to difficulties related to the unpredictable nature of the disease and to the specific target population.

Keywords: RSV; antiviral therapy; pneumonia; respiratory virus; vaccine.

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Structure of Respiratory Syncytial Virus (RSV).
Figure 2
Figure 2
Binding and entry of Respiratory Syncytial Virus (RSV) into the host cell.

References

    1. Heinonen S., Rodriguez-Fernandez R., Diaz A., Rodriguez-Pastor S.O., Ramilo O., Mejias A. Infant immune response to respiratory viral infections. Immunol. Allergy Clin. N. Am. 2019;39:361–376. doi: 10.1016/j.iac.2019.03.005.
    1. Lozano R., Naghavi M., Foreman K., Lim S., Shibuya K., Aboyans V., Abraham J., Adair T., Aggarwal R., Ahn S.Y., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–2128. doi: 10.1016/S0140-6736(12)61728-0.
    1. Yu J., Liu C., Xiao Y., Xiang Z., Zhou H., Chen L., Shen K., Xie Z., Ren L., Wang J. Respiratory syncytial virus seasonality, Beijing, China, 2007–2015. Emerg. Infect. Dis. 2019;25:1127–1135. doi: 10.3201/eid2506.180532.
    1. Jain S., Williams D.J., Arnold S.R., Ampofo K., Bramley A.M., Reed C., Stockmann C., Anderson E.J., Grijalva C.G., Self W.H., et al. Community-Acquired pneumonia requiring hospitalization among U.S. children. N. Engl. J. Med. 2015;372:835–845. doi: 10.1056/NEJMoa1405870.
    1. Stockman L.J., Curns A.T., Anderson L.J., Fischer-Langley G. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997–2006. Pediatrics Infect. Dis. J. 2012;31:5–9. doi: 10.1097/INF.0b013e31822e68e6.
    1. Esposito S., Bianchini S., Argentiero A., Neglia C., Principi N. How does one choose the appropriate pharmacotherapy for children with lower respiratory tract infections? Expert Opin. Pharmacother. 2020;21:1–9. doi: 10.1080/14656566.2020.1781091.
    1. World Health Organization Pneumonia. [(accessed on 7 September 2020)]; Available online: .
    1. Taylor S.M., Lopez P., Weckx L., Borja-Tabora C., Ulloa-Gutierrez R., Lazcano-Ponce E., Kerdpanich A., Weber M.A.R., Santos A.M.D.L., Tinoco J.-C., et al. Respiratory viruses and influenza-like illness: Epidemiology and outcomes in children aged 6 months to 10 years in a multi-country population sample. J. Infect. 2017;74:29–41. doi: 10.1016/j.jinf.2016.09.003.
    1. Pavia A.T. Viral infections of the lower respiratory tract: Old viruses, new viruses, and the role of diagnosis. Clin. Infect. Dis. 2011;52:S284–S289. doi: 10.1093/cid/cir043.
    1. Rey-Jurado E., Kalergis A.M. Immunological features of respiratory syncytial virus-caused pneumonia—Implications for vaccine design. Int. J. Mol. Sci. 2017;18:556. doi: 10.3390/ijms18030556.
    1. Bosis S., Esposito S., Niesters H.G.M., Zuccotti G.V., Marseglia G., Lanari M., Zuin G., Pelucchi C., Osterhaus A.D.M.E., Principi N. Role of respiratory pathogens in infants hospitalized for a first episode of wheezing and their impact on recurrences. Clin. Microbiol. Infect. 2008;14:677–684. doi: 10.1111/j.1469-0691.2008.02016.x.
    1. Taleb S.A., Al Thani A.A., Al Ansari K., Yassine H.M. Human respiratory syncytial virus: Pathogenesis, immune responses, and current vaccine approaches. Eur. J. Clin. Microbiol. Infect. Dis. 2018;37:1817–1827. doi: 10.1007/s10096-018-3289-4.
    1. Nair H., Nokes D.J., Gessner B.D., Dherani M., Madhi S.A., Singleton R.J., O’Brien K.L., Roca A., Wright P.F., Bruce N., et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and meta-analysis. Lancet. 2010;375:1545–1555. doi: 10.1016/S0140-6736(10)60206-1.
    1. World Health Organization WHO Strategy to Pilot Global Respiratory Syncytial Virus Surveillance Based on the Global Influenza Surveillance and Response System (GISRS) [(accessed on 7 September 2020)]; Available online: .
    1. Histoshi T., McAllister D.A., O’Brien K.L., Simoes E.A.F., Madhi S.A., Gessner B.D., Polack F.P., Balsells E., Acacio S., Aguayo C., et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: A systematic review and modelling study. Lancet. 2017;390:946–958. doi: 10.1016/s0140-6736(17)30938-8.
    1. Rath B., Conrad T., Myles P., Alchikh M., Ma X., Hoppe C., Tief F., Chen X., Obermeier P., Kisler B., et al. Influenza and other respiratory viruses: Standardizing disease severity in surveillance and clinical trials. Expert Rev. Anti-Infect. Ther. 2017;15:545–568. doi: 10.1080/14787210.2017.1295847.
    1. Hodgson D., Pebody R., Panovska-Griffiths J., Baguelin M., Atkins K.E. Evaluating the next generation of RSV intervention strategies: A mathematical modelling study and cost-effectiveness analysis. BMC Med. 2020;18:348. doi: 10.1186/s12916-020-01802-8.
    1. Korsun N., Angelova S., Tzotcheva I., Georgieva I., Lazova S., Parina S., Alexiev I., Perenovska P. Prevalence and genetic characterisation of respiratory syncytial viruses circulating in Bulgaria during the 2014/15 and 2015/16 winter seasons. Pathog. Glob. Health. 2017;111:351–361. doi: 10.1080/20477724.2017.1375708.
    1. Baymakova M. Fever of unknown origin in a bulgarian hospital: Evaluation of 54 cases for a four year-period. J. Clin. Anal. Med. 2016;7:70–75. doi: 10.4328/JCAM.3897.
    1. Korsun N., Angelova S., Trifonova I., Voleva S., Grigorova I., Tzotcheva I., Mileva S., Alexiev I., Perenovska P. Predominance of ON1 and BA9 genotypes of Respiratory Syncytial Virus (RSV) in Bulgaria, 2016–2018. J. Med. Virol. 2020;11 doi: 10.1002/jmv.26415.
    1. Pavlova S., Hadzhiolova T., Abadjieva P., Kotseva R. Application of RT-PCR for diagnosis of respiratory syncytial virus and human metapneumovirus infections in Bulgaria, 2006–7 and 2007–8. Eurosurveillance. 2009;14:19233. doi: 10.2807/ese.14.23.19233-en.
    1. Dimova-Yaneva D.N., Helms P.J. The role of leukotrienes and eosinophil cationic protein in acute respiratory syncytial virus bronchiolitis. Folia Med. 2003;45:5–11.
    1. Stein R.T., Bont L.J., Zar H., Polack F.P., Park C., Claxton A., Borok G., Butylkova Y., Wegzyn C.M. Respiratory syncytial virus hospitalization and mortality: Systematic review and meta-analysis. Pediatrics Pulmonol. 2016;52:556–569. doi: 10.1002/ppul.23570.
    1. Blanken M.O., Rovers M.M., Molenaar J.M., Winkler-Seinstra P.L., Meijer A., Kimpen J.L., Bont L., Dutch RSV Neonatal Network Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N. Engl. J. Med. 2013;368:1791–1799. doi: 10.1056/NEJMoa1211917.
    1. Feddema J.J., Claassen E. Prevalence of viral respiratory infections amongst asthmatics: Results of a meta-regression analysis. Respir. Med. 2020;173:106020. doi: 10.1016/j.rmed.2020.106020.
    1. Kitcharoensakkul M., Bacharier L.B., Schweiger T.L., Wilson B., Goss C.W., Lew D., Schechtman K.B., Castro M. Lung function trajectories and bronchial hyperresponsiveness during childhood following severe RSV bronchiolitis in infancy. Pediatrics Allergy Immunol. 2020 doi: 10.1111/pai.13399.
    1. Beigelman A., Bacharier L.B. The role of early life viral bronchiolitis in the inception of asthma. Curr. Opin. Allergy Clin. Immunol. 2013;13:211–216. doi: 10.1097/ACI.0b013e32835eb6ef.
    1. Lim A., Butt M.L., Dix J., Elliott L., Paes B. Respiratory syncytial virus (RSV) infection in children with medical complexity. Eur. J. Clin. Microbiol. Infect. Dis. 2018;38:171–176. doi: 10.1007/s10096-018-3409-1.
    1. Bont L., Checchia P.A., Fauroux B., Figueras-Aloy J., Manzoni P., Paes B., Simões E.A.F., Carbonell-Estrany X. Defining the epidemiology and burden of severe respiratory syncytial virus infection among infants and children in western countries. Infect. Dis. Ther. 2016;5:271–298. doi: 10.1007/s40121-016-0123-0.
    1. Huang Y., Hua J., Wang D., Chen L., Zhang J., Zhu H., Tian J., Zhang T., Zhao G. Risk factors of respiratory syncytial virus infection among pediatric influenza-like illness and severe acute respiratory infections in Suzhou, China. J. Med. Virol. 2018;90:397–404. doi: 10.1002/jmv.24961.
    1. Hall C.B. Respiratory syncytial virus in young children. Lancet. 2010;375:1500–1502. doi: 10.1016/S0140-6736(10)60401-1.
    1. Griffiths C., Drews S.J., Marchant D.J. Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment. Clin. Microbiol. Rev. 2017;30:277–319. doi: 10.1128/CMR.00010-16.
    1. Mazur N.I., Martinón-Torres F., Baraldi E., Fauroux B., Greenough A., Heikkinen T., Manzoni P., Mejias A., Nair H., Papadopoulos N.G., et al. Lower respiratory tract infection caused by respiratory syncytial virus: Current management and new therapeutics. Lancet Respir. Med. 2015;3:888–900. doi: 10.1016/S2213-2600(15)00255-6.
    1. Green C.A., Sande C., De Lara C., Thompson A., Silva-Reyes L., Napolitano F., Pierantoni A., Capone S., Vitelli A., Klenerman P., et al. Humoral and cellular immunity to RSV in infants, children and adults. Vaccine. 2018;36:6183–6190. doi: 10.1016/j.vaccine.2018.08.056.
    1. Beckhaus A.A., Castro-Rodriguez J.A. Down Syndrome and the Risk of Severe RSV Infection: A Meta-analysis. Pediatrics. 2018;142:e20180225. doi: 10.1542/peds.2018-0225.
    1. Shi T., McLean K., Campbell H., Nair H. Aetiological role of common respiratory viruses in acute lower respiratory infections in children under five years: A systematic review and meta-analysis. J. Glob. Health. 2015;5:010408. doi: 10.7189/jogh.05.010408.
    1. Murray A., Chu H.Y. RSV, antibodies and the developing world. Pediatrics Infect. Dis. J. 2019;38:S24–S27. doi: 10.1097/INF.0000000000002333.
    1. Cohen E., Kuo D.Z., Agrawal R., Berry J.G., Bhagat S.K.M., Simon T.D., Srivastava R. Children with medical complexity: An emerging population for clinical and research initiatives. Pediatrics. 2011;127:529–538. doi: 10.1542/peds.2010-0910.
    1. Leyenaar J.K., Lagu T., Shieh M.-S., Pekow P.S., Lindenauer P.K. Management and outcomes of pneumonia among children with complex chronic conditions. Pediatr. Infect. Dis. J. 2014;33:907–911. doi: 10.1097/INF.0000000000000317.
    1. Manzoni P., Figueras-Aloy J., Simões E.A.F., Checchia P.A., Fauroux B., Bont L., Paes B., Carbonell-Estrany X. Defining the incidence and associated morbidity and mortality of severe respiratory syncytial virus infection among children with chronic diseases. Infect. Dis. Ther. 2017;6:383–411. doi: 10.1007/s40121-017-0160-3.
    1. Murray J., Bottle A., Sharland M., Modi N., Aylin P., Majeed A., Saxena S., On Behalf of the Medicines for Neonates Investigator Group Risk factors for hospital admission with RSV bronchiolitis in England: A population-based birth cohort study. PLoS ONE. 2014;9:e89186. doi: 10.1371/journal.pone.0089186.
    1. World Health Organization WHO RSV Surveillance Phase-2 (2019–2021) [(accessed on 7 September 2020)]; Available online:
    1. Lam T.T., Tang J.W., Lai F.Y., Zaraket H., Dbaibo G., Bialasiewicz S., Tozer S., Heraud J.-M., Drews S.J., Hachette T., et al. Comparative global epidemiology of influenza, respiratory syncytial and parainfluenza viruses, 2010–2015. J. Infect. 2019;79:373–382. doi: 10.1016/j.jinf.2019.07.008.
    1. Walker C.L., Rudan I., Liu L., Nair H., Theodoratou E., Bhutta Z.A., O’Brien K.L., Campbell H., Black R.E. Global burden of childhood pneumonia and diarrhea. Lancet. 2013;381:1405–1416. doi: 10.1016/S0140-6736(13)60222-6.
    1. Liu L., Oza S., Hogan D., Chu Y., Perin J., Zhu J., Lawn J.E., Cousens S., Mathers C., Black R.E. Global, regional, and national causes of under-5 mortality in 2000–2015: An updated systematic analysis with implications for the Sustainable Development Goals. Lancet. 2016;388:3027–3035. doi: 10.1016/S0140-6736(16)31593-8.
    1. Prayle A.P., Atkinson M., Smyth A.R. Pneumonia in the developed world. Paediatr. Respir. Rev. 2011;12:60–69. doi: 10.1016/j.prrv.2010.09.012.
    1. Berg A.S., Inchley C.S., Aase A., Fjaerli H.O., Bull R., Aaberge I., Leegaard T.M., Nakstad B. Etiology of pneumonia in a pediatric population with high pneumococcal vaccine coverage: A prospective study. Pediatrics Infect. Dis. J. 2016;35:e69–e75. doi: 10.1097/INF.0000000000001009.
    1. Tian D.-D., Jiang R., Chen X.-J., Ye Q. Meteorological factors on the incidence of MP and RSV pneumonia in children. PLoS ONE. 2017;12:e0173409. doi: 10.1371/journal.pone.0173409.
    1. Du Prel J., Puppe W., Gröndahl B., Knuf M., Weigl J.A.I., Schaaff F., Schmitt H. Are meteorological parameters associated with acute respiratory tract infections? Clin. Infect. Dis. 2009;49:861–868. doi: 10.1086/605435.
    1. O’Brien K.L., Baggett H.C., Brooks W.A., Feikin D.R., Hammitt L.L., Higdon M.M., Howie S.R., Knoll M.D., Kotloff K.L., Levine O.S., et al. Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: The PERCH multi-country case-control study. Lancet. 2019;394:757–779. doi: 10.1016/S0140-6736(19)30721-4.
    1. Levine O.S., O’Brien K.L., Deloria-Knoll M., Murdoch D.R., Feikin D.R., DeLuca A.N., Driscoll A.J., Baggett H.C., Brooks W.A., Howie S.R.C., et al. The pneumonia etiology research for child health project: A 21st century childhood pneumonia etiology study. Clin. Infect. Dis. 2012;54:S93–S101. doi: 10.1093/cid/cir1052.
    1. Scott J.A.G., Wonodi C., Moïsi J.C., Deloria-Knoll M., DeLuca A.N., Karron R.A., Bhat N., Murdoch D.R., Crawley J., Levine O.S., et al. The definition of pneumonia, the assessment of severity, and clinical standardization in the pneumonia etiology research for child health study. Clin. Infect. Dis. 2012;54:S109–S116. doi: 10.1093/cid/cir1065.
    1. Knoll M.D., Feikin D.R., Scott J.A.G., O’Brien K.L., DeLuca A., Driscoll A.J., Levine O.S., The Pneumonia Methods Working Group Identification and selection of cases and controls in the pneumonia etiology research for child health project. Clin. Infect. Dis. 2012;54:S117–S123. doi: 10.1093/cid/cir1066.
    1. Higdon M.M., Le T., O’Brien K.L., Murdoch D.R., Prosperi C., Baggett H.C., Brooks W.A., Feikin D.R., Hammitt L.L., Howie S.R.C., et al. Association of C-reactive protein with bacterial and respiratory syncytial virus-associated pneumonia among children aged <5 years in the PERCH Study. Clin. Infect. Dis. 2017;64:S378–S386.
    1. Bénet T., Picot V.S., Messaoudi M., Chou M., Eap T., Wang J., Shen K., Pape J.-W., Rouzier V., Awasthi S., et al. Microorganisms associated with pneumonia in children <5 years of age in developing and emerging countries: The GABRIEL Pneumonia Multicenter, prospective, case-control study. Clin. Infect. Dis. 2017;65:604–612.
    1. Bhuiyan M.U., Snelling T.L., West R., Lang J., Rahman T., Granland C., De Gier C., Borland M.L., Thornton R.B., Kirkham L.-A.S., et al. The contribution of viruses and bacteria to community-acquired pneumonia in vaccinated children: A case-control study. Thorax. 2019;74:261–269. doi: 10.1136/thoraxjnl-2018-212096.
    1. Nascimento-Carvalho A.C., Vilas-Boas A.-L., Fontoura M.-S.H., Vuorinen T., Nascimento-Carvalho C.M., PNEUMOPAC-Efficacy Study Group Respiratory viruses among children with non-severe community-acquired pneumonia: A prospective cohort study. J. Clin. Virol. 2018;105:77–83. doi: 10.1016/j.jcv.2018.06.003.
    1. Khuri-Bulos N., Lawrence L., Piya B., Wang L., Fonnesbeck C., Faouri S., Shehabi A., Vermund S.H., Williams J.V., Halasa N.B. Severe outcomes associated with respiratory viruses in newborns and infants: A prospective viral surveillance study in Jordan. BMJ Open. 2018;8:e021898. doi: 10.1136/bmjopen-2018-021898.
    1. Romero-Espinoza J.A., Moreno-Valencia Y., Coronel-Tellez R.H., Torres-Espíndola L.M., Hernández A., Dominguez A., Miliar-García A., Barbachano-Guerrero A., Perez-Padilla R., Alejandre-Garcia A., et al. Virome and bacteriome characterization of children with pneumonia and asthma in Mexico City during winter seasons 2014 and 2015. PLoS ONE. 2018;13:e0192878. doi: 10.1371/journal.pone.0192878.
    1. Ching N.S., Kotsanas D., Easton M.L., Francis M.J., Korman T.M., Buttery J.P. Respiratory virus detection and co-infection in children and adults in a large Australian hospital in 2009–2015. J. Paediatr. Child. Health. 2018;54:1321–1328. doi: 10.1111/jpc.14076.
    1. Esposito S., Piralla A., Zampiero A., Bianchini S., Di Pietro G., Scala A., Pinzani R., Fossali E., Baldanti F., Principi N. Characteristics and their clinical relevance of respiratory syncytial virus types and genotypes circulating in northern Italy in five consecutive winter seasons. PLoS ONE. 2015;10:e0129369. doi: 10.1371/journal.pone.0129369.
    1. Kazakova A., Kakkola L., Päkkilä H., Teros-Jaakkola T., Soukka T., Peltola V., Waris M., Julkunen I. Serological array-in-well multiplex assay reveals a high rate of respiratory virus infections and reinfections in young children. mSphere. 2019;4:e00447-19. doi: 10.1128/mSphere.00447-19.
    1. Hall C.B., Weinberg G.A., Iwane M.K., Blumkin A.K., Edwards K.M., Staat M.A., Auinger P., Griffin M.R., Poehling K.A., Erdman D., et al. The burden of respiratory syncytial virus infection in young children. N. Engl. J. Med. 2009;360:588–598. doi: 10.1056/NEJMoa0804877.
    1. Graham B.S. Vaccine development for respiratory syncytial virus. Curr. Opin. Virol. 2017;23:107–112. doi: 10.1016/j.coviro.2017.03.012.
    1. Welliver T.P., Garofalo R.P., Hosakote Y., Hintz K.H., Avendano L., Sanchez K., Velozo L., Jafri H., Chavez-Bueno S., Ogra P.L., et al. Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J. Infect. Dis. 2007;195:1126–1136. doi: 10.1086/512615.
    1. Villenave R., Thavagnanam S., Sarlang S., Parker J., Douglas I., Skibinski G., Heaney L.G., McKaigue J.P., Coyle P.V., Shields M.D., et al. In vitro modeling of respiratory syncytial virus infection of pediatric bronchial epithelium, the primary target of infection in vivo. Proc. Natl. Acad. Sci. USA. 2012;109:5040–5045. doi: 10.1073/pnas.1110203109.
    1. Teng M.N., Whitehead S.S., Collins P.L. Contribution of the respiratory syncytial virus g glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. Virology. 2001;289:283–296. doi: 10.1006/viro.2001.1138.
    1. Lay M.K., González P.A., León M.A., Céspedes P.F., Bueno S.M., Riedel C.A., Kalergis A.M. Advances in understanding respiratory syncytial virus infection in airway epithelial cells and consequential effects on the immune response. Microbes Infect. 2013;15:230–242. doi: 10.1016/j.micinf.2012.11.012.
    1. Rossi G.A., Colin A.A. Infantile respiratory syncytial virus and human rhinovirus infections: Respective role in inception and persistence of wheezing. Eur. Respir. J. 2014;45:774–789. doi: 10.1183/09031936.00062714.
    1. Guo-Parke H., Canning P., Douglas I., Villenave R., Heaney L.G., Coyle P.V., Lyons J.D., Shields M.D., Power U.F. Relative respiratory syncytial virus cytopathogenesis in upper and lower respiratory tract epithelium. Am. J. Respir. Crit. Care Med. 2013;188:842–851. doi: 10.1164/rccm.201304-0750OC.
    1. Legg J.P., Hussain I.R., Warner J.A., Johnston S.L., Warner J.O. Type 1 and Type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis. Am. J. Respir. Crit. Care Med. 2003;168:633–639. doi: 10.1164/rccm.200210-1148OC.
    1. Johnson J.E., A Gonzales R., Olson S.J., Wright P.F., Graham B.S. The histopathology of fatal untreated human respiratory syncytial virus infection. Mod. Pathol. 2007;20:108–119. doi: 10.1038/modpathol.3800725.
    1. Noor A., Krilov L.R. Respiratory syncytial virus vaccine: Where are we now and what comes next? Expert Opin. Biol. Ther. 2018;18:1247–1256. doi: 10.1080/14712598.2018.1544239.
    1. González-Parra G., Dobrovolny H.M. A quantitative assessment of dynamical differences of RSV infections in vitro and in vivo. Virology. 2018;523:129–139. doi: 10.1016/j.virol.2018.07.027.
    1. Roe M., O’Donnell D., Callif C.G. Respiratory viruses in the intensive care unit. Paediatr. Respir. Rev. 2003;4:166–171. doi: 10.1016/S1526-0542(03)00056-3.
    1. Cherian T., Mulholland E.K., Carlin J.B., Ostensen H., Amin R., De Campo M., Greenberg D., Lagos R., Lucero M., Madhi S.A., et al. Standardized interpretation of paediatric chest radiographs for the diagnosis of pneumonia in epidemiological studies. Bull. World Health Organ. 2005;83:353–359.
    1. Fancourt N., Knoll M.D., Barger-Kamate B., De Campo J., De Campo M., Diallo M., Ebruke B.E., Feikin D.R., Gleeson F., Gong W., et al. standardized interpretation of chest radiographs in cases of pediatric pneumonia from the PERCH study. Clin. Infect. Dis. 2017;64:S253–S261. doi: 10.1093/cid/cix082.
    1. Esposito S., Mencacci A., Cenci E., Camilloni B., Silvestri E., Principi N. Multiplex platforms for the identification of respiratory pathogens: Are they useful in pediatric clinical practice? Front. Cell. Infect. Microbiol. 2019;9:196. doi: 10.3389/fcimb.2019.00196.
    1. Rodriguez-Fernandez R., Tapia L.I., Yang C.-F., Torres J.P., Chavez-Bueno S., Garcia C., Jaramillo L.M., Moore-Clingenpeel M., Jafri H.S., Peeples M.E., et al. Respiratory syncytial virus genotypes, host immune profiles, and disease severity in young children hospitalized with bronchiolitis. J. Infect. Dis. 2018;217:24–34. doi: 10.1093/infdis/jix543.
    1. Shi T., Balsells E., Wastnedge E., Singleton R., Rasmussen Z.A., Zar H.J., Rath B.A., Madhi S.A., Campbell S., Vaccari L.C., et al. Risk factors for respiratory syncytial virus associated with acute lower respiratory infection in children under five years: Systematic review and meta–analysis. J. Glob. Health. 2015;5:020416. doi: 10.7189/jogh.05.020416.
    1. Ravindranath T.M., Gomez A., Harwayne-Gidansky I., Connors T.J., Neill N., Levin B., Howell J.D., Saiman L., Baird J.S. Pediatric acute respiratory distress syndrome associated with human metapneumovirus and respiratory syncytial virus. Pediatrics Pulmonol. 2018;53:929–935. doi: 10.1002/ppul.24044.
    1. Agoti C.N., Mwihuri A.G., Sande C.J., Onyango C.O., Medley G.F., Cane P.A., Nokes D.J. Genetic relatedness of infecting and reinfecting respiratory syncytial virus strains identified in a birth cohort from rural Kenya. J. Infect. Dis. 2012;206:1532–1541. doi: 10.1093/infdis/jis570.
    1. Openshaw P.J., Chiu C., Culley F.J., Johansson C. Protective and harmful immunity to RSV infection. Annu. Rev. Immunol. 2017;35:501–532. doi: 10.1146/annurev-immunol-051116-052206.
    1. Netea M.G., Joosten L.A.B., Latz E., Mills K.H.G., Natoli G., Stunnenberg H.G., O’Neill L.A.J., Xavier R.J. Trained immunity: A program of innate immune memory in health and disease. Science. 2016;352:aaf1098. doi: 10.1126/science.aaf1098.
    1. Kusel M.M., Kebadze T., Johnston S.L., Holt P.G., Sly P.D. Febrile respiratory illnesses in infancy and atopy are risk factors for persistent asthma and wheeze. Eur. Respir. J. 2011;39:876–882. doi: 10.1183/09031936.00193310.
    1. Coverstone A.M., Wang L., Sumino K. Beyond respiratory syncytial virus and rhinovirus in the pathogenesis and exacerbation of asthma: The role of metapneumovirus, bocavirus and influenza virus. Immunol. Allergy Clin. N. Am. 2019;39:391–401. doi: 10.1016/j.iac.2019.03.007.
    1. Bacharier L.B., Cohen R., Schweiger T., Yin-DeClue H., Christie C., Zheng J., Schechtman K.B., Strunk R.C., Castro M. Determinants of asthma after severe respiratory syncytial virus bronchiolitis. J. Allergy Clin. Immunol. 2012;130:91–100. doi: 10.1016/j.jaci.2012.02.010.
    1. Sigurs N., AlJassim F., Kjellman B., Robinson P.D., Sigurbergsson F., Bjarnason R., Gustafsson P.M. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax. 2010;65:1045–1052. doi: 10.1136/thx.2009.121582.
    1. Mohapatra S.S., Boyapalle S. Epidemiologic, experimental, and clinical links between respiratory syncytial virus infection and asthma. Clin. Microbiol. Rev. 2008;21:495–504. doi: 10.1128/CMR.00054-07.
    1. Daley D., Park J.E., He J.-Q., Yan J., Akhabir L., Stefanowicz D., Becker A., Chan-Yeung M., Bossé Y., Kozyrskyj A.L., et al. Associations and interactions of genetic polymorphisms in innate immunity genes with early viral infections and susceptibility to asthma and asthma-related phenotypes. J. Allergy Clin. Immunol. 2012;130:1284–1293. doi: 10.1016/j.jaci.2012.07.051.
    1. James K.M., Peebles R.S., Jr., Hartert T.V. Response to infections in patients with asthma and atopic disease: An epiphenomenon or reflection of host susceptibility? J. Allergy Clin. Immunol. 2012;130:343–351. doi: 10.1016/j.jaci.2012.05.056.
    1. Ferronato Â.E., Gilio A.E., Ferraro A.A., De Paulis M., Vieira S.E. Etiological diagnosis reduces the use of antibiotics in infants with bronchiolitis. Clinics. 2012;67:1007–1011. doi: 10.6061/clinics/2012(09)03.
    1. Hogan C.A., Caya C., Papenburg J. Rapid and simple molecular tests for the detection of respiratory syncytial virus: A review. Expert Rev. Mol. Diagn. 2018;18:617–629. doi: 10.1080/14737159.2018.1487293.
    1. Mahony J.B., Blackhouse G., Babwah J., Smieja M., Buracond S., Chong S., Ciccotelli W., O’Shea T., Alnakhli D., Griffiths-Turner M., et al. Cost analysis of multiplex PCR testing for diagnosing respiratory virus infections. J. Clin. Microbiol. 2009;47:2812–2817. doi: 10.1128/JCM.00556-09.
    1. Chartrand C., Tremblay N., Renaud C., Papenburg J. Diagnostic accuracy of rapid antigen detection tests for respiratory syncytial virus infection: Systematic review and meta-analysis. J. Clin. Microbiol. 2015;53:3738–3749. doi: 10.1128/JCM.01816-15.
    1. Papenburg J., Buckeridge D.L., De Serres G., Boivin G. Host and viral factors affecting clinical performance of a rapid diagnostic test for respiratory syncytial virus in hospitalized children. J. Pediatrics. 2013;163:911–913. doi: 10.1016/j.jpeds.2013.03.067.
    1. Chan M., Koo S.H., Jiang B., Lim P.Q., Tan T.-Y. Comparison of the biofire filmarray respiratory panel, seegene AnyplexII RV16, and Argene for the detection of respiratory viruses. J. Clin. Virol. 2018;106:13–17. doi: 10.1016/j.jcv.2018.07.002.
    1. Beckmann C., Hirsch H.H. Comparing luminex NxTAG-respiratory pathogen panel and respifinder-22 for multiplex detection of respiratory pathogens. J. Med. Virol. 2016;88:1319–1324. doi: 10.1002/jmv.24492.
    1. Moe N., Pedersen B., Nordbø S.A., Skanke L.H., Krokstad S., Smyrnaios A., Døllner H. Respiratory virus detection and clinical diagnosis in children attending day care. PLoS ONE. 2016;11:e0159196. doi: 10.1371/journal.pone.0159196.
    1. Turi K.N., Romick-Rosendale L., Gebretsadik T., Watanabe M., Brunwasser S., Anderson L.J., Moore M.L., Larkin E.K., Peebles R.S., Hartert T.V. Using urine metabolomics to understand the pathogenesis of infant respiratory syncytial virus (RSV) infection and its role in childhood wheezing. Metabolomics. 2018;14:135. doi: 10.1007/s11306-018-1431-z.
    1. Barr R., Green C.A., Sande C.J., Drysdale S.B. Respiratory syncytial virus: Diagnosis, prevention and management. Ther. Adv. Infect. Dis. 2019;6 doi: 10.1177/2049936119865798.
    1. National Institute for Health and Care Excellence Bronchiolitis in Children: Diagnosis and Management. NICE Guideline [NG9] [(accessed on 7 September 2020)];2015 Available online: .
    1. Xing Y., Proesmans M. New therapies for acute RSV infections: Where are we? Eur. J. Pediatrics. 2019;178:131–138. doi: 10.1007/s00431-018-03310-7.
    1. Simões E.A.F., DeVincenzo J.P., Boeckh M., Bont L., Crowe J.E., Griffiths P., Hayden F.G., Hodinka R.L., Smyth R.L., Spencer K., et al. Challenges and opportunities in developing respiratory syncytial virus therapeutics. J. Infect. Dis. 2015;211:S1–S20. doi: 10.1093/infdis/jiu828.
    1. Jorquera P.A., Tripp R.A. Respiratory syncytial virus: Prospects for new and emerging therapeutics. Expert Rev. Respir. Med. 2017;11:609–615. doi: 10.1080/17476348.2017.1338567.
    1. Heylen E., Neyts J., Jochmans D. Drug candidates and model systems in respiratory syncytial virus antiviral drug discovery. Biochem. Pharmacol. 2017;127:1–12. doi: 10.1016/j.bcp.2016.09.014.
    1. Ke Z., Dillard R.S., Chirkova T., Leon F., Stobart C.C., Hampton C.M., Strauss J.D., Rajan D., Rostad C.A., Taylor J.V., et al. The morphology and assembly of respiratory syncytial virus revealed by cryo-electron tomography. Viruses. 2018;10:446. doi: 10.3390/v10080446.
    1. Graham B.S., Modjarrad K., McLellan J.S. Novel antigens for RSV vaccines. Curr. Opin. Immunol. 2015;35:30–38. doi: 10.1016/j.coi.2015.04.005.
    1. Ralston S.L., Lieberthal A.S., Meissner H.C., Alverson B.K., Baley J.E., Gadomski A.M., Johnson D.W., Light M.J., Maraqa N.F., Mendonca E.A., et al. Clinical practice guideline: The diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014;134:e1474–e1502. doi: 10.1542/peds.2014-2742.
    1. Walpert A.S., Thomas I.D., Lowe M.C., Jr., Seckeler M.D. RSV prophylaxis guideline changes and outcomes in children with congenital heart disease. Congenit. Heart Dis. 2018;13:428–431. doi: 10.1111/chd.12590.
    1. Blake S.M., Tanaka D., Bendz L.M., Staebler S., Brandon D. Evaluation of the financial and health burden of infants at risk for respiratory syncytial virus. Adv. Neonatal Care. 2017;17:292–298. doi: 10.1097/ANC.0000000000000367.
    1. Ambrose C.S., Chen X., Kumar V.R. A population-weighted, condition-adjusted estimate of palivizumab efficacy in preventing RSV-related hospitalizations among US high-risk children. Hum. Vaccines Immunother. 2014;10:2785–2788. doi: 10.4161/hv.32082.
    1. Domachowske J.B., Khan A.A., Esser M.T., Jensen K., Takas T., Villafana T., Dubovsky F., Griffin M.P. Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants. Pediatrics Infect. Dis. J. 2018;37:886–892. doi: 10.1097/INF.0000000000001916.
    1. Bianchini S., Argentiero A., Camilloni B., Silvestri E., Alunno A., Esposito S. Vaccination against paediatric respiratory pathogens. Vaccines. 2019;7:168. doi: 10.3390/vaccines7040168.
    1. Esposito S., Scarselli E., Lelii M., Scala A., Vitelli A., Capone S., Fornili M., Biganzoli E., Orenti A., Nicosia A., et al. Antibody response to respiratory syncytial virus infection in children <18 months old. Hum. Vaccines Immunother. 2016;12:1700–1706.
    1. Rostad C.A., Stobart C.C., Gilbert B.E., Pickles R.J., Hotard A.L., Meng J., Blanco J.C.G., Moin S.M., Graham B.S., Piedra P.A., et al. A recombinant respiratory syncytial virus vaccine candidate attenuated by a low-fusion F protein is immunogenic and protective against challenge in cotton rats. J. Virol. 2016;90:7508–7518. doi: 10.1128/JVI.00012-16.
    1. Melero J.A., Mas V., McLellan J.S. Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development. Vaccine. 2017;35:461–468. doi: 10.1016/j.vaccine.2016.09.045.
    1. Mazur N.I., Higgins D., Nunes M.C., Melero J.A., Langedijk A.C., Horsley N., Buchholz U.J., Openshaw P.J., McLellan J.S., A Englund J., et al. The respiratory syncytial virus vaccine landscape: Lessons from the graveyard and promising candidates. Lancet Infect. Dis. 2018;18:e295–e311. doi: 10.1016/S1473-3099(18)30292-5.
    1. Crank M.C., Ruckwardt T.J., Chen M., Morabito K.M., Phung E., Costner P.J., Holman L.A., Hickman S.P., Berkowitz N.M., Gordon I.J., et al. A proof of concept for structure-based vaccine design targeting RSV in humans. Science. 2019;365:505–509. doi: 10.1126/science.aav9033.
    1. Giersing B.K., Modjarrad K., Kaslow D.C., Moorthy V.S., WHO Product Development for Vaccines Advisory Committee. WHO Product Development for Vaccines Product Development Advisory Committee Report from the World Health Organization’s Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 7–9th September 2015. Vaccine. 2016;34:2865–2869. doi: 10.1016/j.vaccine.2016.02.078.
    1. Abu-Raya B., Maertens K., Edwards K.M., Omer S.B., Englund J.A., Flanagan K.L., Snape M.D., Amirthalingam G., Leuridan E., Van Damme P., et al. Global perspectives on immunization during pregnancy and priorities for future research and development: An international consensus statement. Front. Immunol. 2020;11:1282. doi: 10.3389/fimmu.2020.01282.
    1. Esposito S., Principi N. Strategies to develop vaccines of pediatric interest. Expert Rev. Vaccines. 2017:175–186. doi: 10.1080/14760584.2017.1237875.
    1. Chirkova T., Lin S., Oomens A.G.P., Gaston K.A., Boyoglu-Barnum S., Meng J., Stobart C.C., Cotton C.U., Hartert T.V., Moore M.L., et al. CX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells. J. Gen. Virol. 2015;96:2543–2556. doi: 10.1099/vir.0.000218.
    1. Marr N., Turvey S.E. Role of human TLR4 in respiratory syncytial virus-induced NF-κB activation, viral entry and replication. Innate Immun. 2012;18:856–865. doi: 10.1177/1753425912444479.
    1. Tayyari F., Marchant D.R., Moraes T.J., Duan W., Mastrangelo P., Hegele R.G. Identification of nucleolin as a cellular receptor for human respiratory syncytial virus. Nat. Med. 2011;17:1132–1135. doi: 10.1038/nm.2444.
    1. Clinical Trials Gov RSV Infection. [(accessed on 7 September 2020)]; Available online:

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi